# Neoadjuvant Therapy for Locally Advanced Colon Cancer

> **NCT04625803** · PHASE2 · COMPLETED · sponsor: **Zhejiang University** · enrollment: 64 (actual)

## Conditions studied

- Colon Cancer
- Neoadjuvant Therapy

## Interventions

- **DRUG:** Camrelizumab , apatinib and chemotherapy

## Key facts

- **NCT ID:** NCT04625803
- **Lead sponsor:** Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-04
- **Primary completion:** 2023-09-30
- **Final completion:** 2023-09-30
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2025-06-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04625803

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04625803, "Neoadjuvant Therapy for Locally Advanced Colon Cancer". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT04625803. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*